Granted Patent B1

US 9,090,689 · App. 14/681,704 · Granted Jul 28, 2015

Inventors: Rebecca S. Hoffman (Wilmette, IL); Mark Weinberg (Northbrook, IL); Subhashis Banerjee (Princeton, NJ); Lori K. Taylor (Boston, MA); Clive E. Spiegler (Skillman, NJ); Daniel E. Tracey (Harvard, MA); Elliot K. Chartash (Marietta, GA); William T. Barchuk (San Diego, CA); Philip Yan (Vernon Hills, IL); Anwar Murtaza (Westborough, MA); Jochen G. Salfeld (North Grafton, MA); Steven A. Fischkoff (Short Hills, NJ); George R. Granneman (Marco Island, FL)

Assignee: AbbVie Biotechnology Ltd.

C07K16/241C07K2317/21C07K2317/76

Abstract

Claims (21)

1. A method of administering adalimumab for treatment of moderate to severe chronic plaque psoriasis, comprising filling adalimumab into vessels and subcutaneously administering 40 mg of said adalimumab to a patient having moderate to severe chronic plaque psoriasis every other week.

2. The method of claim 1 , wherein adalimumab in said vessels is formulated at a concentration of 50 mg/ml.

3. The method of claim 2 , wherein said vessels each contains 40 mg of adalimumab.

4. The method of claim 1 , wherein said vessels are syringes.

5. The method of claim 4 , wherein adalimumab in said syringes is formulated at a concentration of 50 mg/ml.

6. The method of claim 5 , wherein said syringes each contains 40 mg of adalimumab.

7. A method of preparing adalimumab for treating moderate to severe chronic plaque psoriasis, comprising filling adalimumab into vessels and providing said adalimumab for treatment, wherein said treatment comprises subcutaneously administering 40 mg of said adalimumab to a patient having moderate to severe chronic plaque psoriasis every other week.

8. The method of claim 7 , wherein adalimumab in said vessels is formulated at a concentration of 50 mg/ml.

9. The method of claim 8 , wherein said vessels each contains 40 mg of adalimumab.

10. The method of claim 7 , wherein said vessels are syringes.

11. The method of claim 10 , wherein adalimumab in said syringes is formulated at a concentration of 50 mg/ml.

12. The method of claim 11 , wherein said syringes each contains 40 mg of adalimumab.

13. The method of claim 7 , wherein at least 5% body surface area (BSA) of the patient is affected by the psoriasis.

14. The method of claim 13 , wherein adalimumab in said vessels is formulated at a concentration of 50 mg/ml.

15. The method of claim 14 , wherein each said vessels are syringes and each contains 40 mg of adalimumab.

16. The method of claim 7 , wherein said patient has both psoriasis and psoriatic arthritis and achieves at least a 75% reduction in Psoriasis Area and Severity Index (PASI) score at week 12 of the treatment.

17. The method of claim 16 , wherein adalimumab in said vessels is formulated at a concentration of 50 mg/ml.

18. The method of claim 17 , wherein each said vessels are syringes and each contains 40 mg of adalimumab.

19. The method of claim 7 , wherein said patient has both psoriasis and psoriatic arthritis and achieves at least a Physician Global Assessment (PGA) score of clear or almost clear at week 12 of the treatment.

20. The method of claim 19 , wherein adalimumab in said vessels is formulated at a concentration of 50 mg/ml.

21. The method of claim 20 , wherein each said vessels are syringes and each contains 40 mg of adalimumab.

Assignments (1)

Continuity (15)